MedMira Secures Health Canada Approval for Reveal G4 Rapid HIV Test

MedMira Inc. (MedMira) announced that it has secured approval from Health Canada for its Reveal Rapid G4 HIV-1/2 Test (Reveal HIV test) intended for Point-of-Care (POC) applications. The Reveal HIV rapid test boasts a sensitivity of 99.64% and a specificity of 99.71%, making it ideal for healthcare professionals needing quick, trustworthy, and high-quality results applicable in any healthcare environment.

The Reveal HIV test allows for an instant result to precisely identify HIV-1/2 antibodies with merely a tiny sample taken from a finger prick. The simple steps, taking less than 1 minute to finish the test (post-sample collection), enable an operator to obtain a result that is immediate and does not diminish. The lack of special storage needs, combined with this aspect, makes the Reveal HIV test an excellent option for any healthcare environment.

The product utilizes MedMira’s distinctive and patented Rapid Vertical Flow Technology, featuring an integrated reagent and procedural control line that assures users that the test is conducted accurately. This unique characteristic offers the assurance and reassurance that a test has been properly finished. A fundamental component for any swift testing, particularly for transformative diagnoses like HIV.